Your trusted source for investing success

Tag: Intellia Therapeutics

Genetics Facts for Investors

Genetics Facts for Investors

Punnett squares and phenotypes, chromatids and codominance: genetics, and all of its associated terms, isn’t the easiest field to understand. And yet experts agree: this is the future of medicine.

Top Biotech News Stories of 2016

Top Biotech News Stories of 2016

The following news stories made headlines in 2016, since they triggered major stock sell-offs in the sector. But it’s not all bad news: a few key events also caused biotech to rally.

CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Global Agreement on the Foundational Intellectual Property for CRISPR/Cas9 Gene Editing Technology

CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences, and ERS Genomics announced that the companies and their licensors have entered into a global cross-consent and invention management agreement for the foundational intellectual property covering CRISPR/Cas9 gene editing technology.

Biotech Investing Basics

Biotech Investing Basics

What is biotech, exactly? Who are its major players and where do they operate? How is this sector changing the life science space … and why do you, as an investor, need to know about it?

What Is CRISPR and Why Should Investors Care?

What Is CRISPR and Why Should Investors Care?

CRISPR-Cas9 is revolutionizing gene engineering. And for those keen on the sector, there is ample opportunity to break into this market, thanks to the rise of CRISPR-based biotechs like Editas Medicine or Intellia Therapeutics. But before you buy in, read on. This emerging technology has plenty of potential—but also a

Enter Your Log In Credentials
This setting should only be used on your home or work computer.

×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network

Send this to a friend

Hi,
I thought you might find this interesting:
4 Gene Therapy Stocks to Watch in 2017

URL: https://investingnews.com/daily/life-science-investing/genetics-investing/4-gene-therapy-stocks-to-watch-2017/